Charles A. B. Boucher

Charles A. B. Boucher's AcademicInfluence.com Rankings

Business

#945

World Rank

#1033

Historical Rank

Risk Management

#28

World Rank

#28

Historical Rank

business Degrees

Download Badge

Business

Why Is Charles A. B. Boucher Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Charles A. B. Boucher's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update (2009) (905)
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir (1996) (788)
Pathogenesis and Transmission of Swine-Origin 2009 A(H1N1) Influenza Virus in Ferrets (2009) (621)
An automated genotyping system for analysis of HIV-1 and other microbial sequences (2005) (517)
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) (2021) (498)
T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). (2000) (490)
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. (2005) (453)
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection (2000) (452)
Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. (1996) (437)
Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. (1992) (428)
Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. (1999) (397)
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. (1992) (378)
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial (2002) (358)
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase (1993) (314)
Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants (2020) (263)
Transmission of drug-resistant HIV-1 is stabilizing in Europe. (2009) (259)
The duration of viral suppression during protease inhibitor therapy for HIV‐1 infection is predicted by plasma HIV‐1 RNA at the nadir (1998) (243)
Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels (2010) (242)
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine (1993) (238)
Worldwide Evaluation of DNA Sequencing Approaches for Identification of Drug Resistance Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (1999) (202)
Implications of antiretroviral resistance on viral fitness (2001) (200)
A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection (2005) (191)
Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. (2010) (184)
Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting (2001) (184)
Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. (2012) (183)
Evolution of Lamivudine Resistance in Human Immunodeficiency Virus Type 1-Infected Individuals: the Relative Roles of Drift and Selection (2000) (180)
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy (1990) (176)
Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (2015) (173)
A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism (2007) (173)
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review (2009) (166)
Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. (1998) (164)
Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. (2006) (161)
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. (1990) (154)
Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. (2011) (148)
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe (2015) (147)
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach (2009) (141)
Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir (2006) (137)
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics (2013) (136)
Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy (2018) (135)
Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase (1997) (134)
Worldwide transmission of drug-resistant HIV. (2003) (131)
Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma (1996) (130)
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. (1995) (130)
Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. (2011) (124)
Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. (1998) (124)
The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes (2006) (115)
Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. (1997) (113)
Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues (2000) (105)
Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. (2002) (105)
HIV‐1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment (1992) (103)
Overshoot of HIV‐1 viraemia after early discontinuation of antiretroviral treatment (1997) (103)
The Dominant Source of CD4+ and CD8+ T‐Cell Activation in HIV Infection Is Antigenic Stimulation (2000) (103)
Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug Resistance (2001) (102)
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus‐associated lymphoproliferative disease after allogeneic stem cell transplantation (2001) (102)
Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. (1994) (101)
Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. (1996) (100)
Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). (2013) (99)
Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time (2010) (98)
In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. (2000) (98)
Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. (2017) (97)
Transmission networks of HIV-1 among men having sex with men in the Netherlands (2010) (96)
From molecule to man: Decision support in individualized E-health (2006) (95)
Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase (2009) (86)
Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. (2000) (85)
A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV‐infected patients (1996) (84)
Vertical HIV-1 transmission correlates with a high maternal viral load at delivery. (1997) (81)
Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy (2009) (81)
Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. (2016) (80)
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay (1996) (79)
Incidence of viral respiratory pathogens causing exacerbations in adult cystic fibrosis patients (2013) (79)
Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. (2009) (77)
Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? (2003) (77)
Stochastic simulation of HIV population dynamics through complex network modelling (2008) (76)
H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis (2012) (76)
Cellular Automata Model of Drug Therapy for HIV Infection (2002) (75)
Clinical diagnosis of influenza virus infection: evaluation of diagnostic tools in general practice. (2001) (74)
Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models (2013) (73)
Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study (2018) (72)
Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. (1996) (72)
Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy (1998) (72)
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. (1997) (70)
Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. (1995) (70)
Evolutionary pathways of transmitted drug-resistant HIV-1. (2011) (70)
Influenza virus resistance to antiviral therapy. (2013) (69)
Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model (1997) (67)
Primary resistance to integrase strand-transfer inhibitors in Europe. (2015) (65)
Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. (1988) (61)
Extracting causal relations on HIV drug resistance from literature (2010) (61)
Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2B: Relation to Response and HBV Genotype (2012) (61)
Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. (2015) (60)
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. (2003) (60)
Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. (1995) (59)
Identifying potential survival strategies of HIV-1 through virus-host protein interaction networks (2010) (59)
HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy (2018) (59)
A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. (2011) (58)
Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (2015) (57)
Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). (1999) (57)
Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates (1993) (55)
Epstein-Barr virus in a CD8-positive T-cell lymphoma. (1990) (55)
Reverse transcriptase fidelity and HIV-1 variation. (1997) (54)
Multidrug Resistant 2009 A/H1N1 Influenza Clinical Isolate with a Neuraminidase I223R Mutation Retains Its Virulence and Transmissibility in Ferrets (2011) (52)
High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands (2018) (51)
The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals (2019) (51)
The global spread of HIV-1 subtype B epidemic (2016) (50)
Anti-CD4 therapy for AIDS suggested by mathematical models (1996) (50)
Acute hepatitis C virus infection. (2008) (50)
Mixed infections of pandemic H1N1 and seasonal H3N2 viruses in 1 outbreak. (2010) (49)
Reconstitution of naive T cells during antiretroviral treatment of HIV-infected adults is dependent on age (2002) (49)
Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap Region (2008) (49)
HIV decision support: from molecule to man (2009) (47)
Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. (1988) (47)
Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine (1998) (46)
Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection (2011) (45)
Identification and treatment of chronic hepatitis B in Chinese migrants: results of a project offering on-site testing in Rotterdam, The Netherlands. (2012) (45)
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients (2007) (45)
Criteria for Drugs Used in Pre-Exposure Prophylaxis Trials against HIV Infection (2006) (45)
Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation. (2007) (45)
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe (2014) (44)
Limited cross-border infections in patients newly diagnosed with HIV in Europe (2013) (44)
Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential. (1999) (43)
First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands. (1996) (43)
Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group (2014) (43)
Therapeutic Drug Monitoring (2012) (43)
Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect. (2001) (42)
Cost-Effectiveness of Pre-Exposure Prophylaxis (PrEP) in Preventing HIV-1 Infections in Rural Zambia: A Modeling Study (2013) (42)
Alternation of Antiretroviral Drug Regimens for HIV Infection (2003) (41)
Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. (2011) (41)
Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. (2009) (41)
Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. (2009) (40)
Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. (1996) (39)
A Grid-Based Hiv Expert System (2005) (39)
Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. (2000) (38)
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. (1997) (37)
Molecular assays for quantitative and qualitative detection of influenza virus and oseltamivir resistance mutations. (2013) (36)
High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis. (2019) (36)
Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal (2015) (36)
A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants. (2006) (36)
Greater diversity of the HIV-1 V3 neutralization domain in Tanzania compared with The Netherlands: serological and genetic analysis. (1993) (35)
An Increase in Viral Replicative Capacity Drives the Evolution of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Drugs (2006) (35)
Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic (2014) (35)
Rational approaches to resistance: using saquinavir. (1996) (34)
Leflunomide as part of the treatment for multidrug‐resistant cytomegalovirus disease after lung transplantation: case report and review of the literature (2013) (34)
Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). (2016) (33)
The risk of HIV drug resistance following implementation of pre-exposure prophylaxis (2010) (33)
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe (2018) (33)
HIV-1 Can Persist in Aged Memory CD4+ T Lymphocytes With Minimal Signs of Evolution After 8.3 Years of Effective Highly Active Antiretroviral Therapy (2009) (33)
RegaDB: community-driven data management and analysis for infectious diseases (2013) (32)
Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. (1994) (32)
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching (2008) (32)
The Epidemiology of Transmission of Drug Resistant HIV-1 (2007) (31)
Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. (1998) (31)
Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men (2019) (30)
An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group. (1999) (30)
The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors (2018) (30)
Phase I/II study of 3TC (lamivudine) in HIV‐positive, asymptomatic or mild AIDS‐related complex patients: sustained reduction in viral markers (1995) (29)
Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17–18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework (2018) (29)
Improving the Prediction of Virological Response to Tipranavir: The Development and Validation of a Tipranavir-Weighted Mutation Score (2010) (28)
Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study (2014) (28)
Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients. (2016) (28)
Benoît Kornmann , by a Synthetic Biology Screen An ER-Mitochondria Tethering Complex Revealed (2009) (27)
Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study (2014) (26)
Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals. (1991) (26)
Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands (2010) (26)
Cost-Effectiveness of PrEP in HIV/AIDS Control in Zambia: A Stochastic League Approach (2014) (26)
Zidovudine plus interferon-α versus zidovudine alone in HIV‐infected symptomatic or asymptomatic persons with CD4+ cell counts > 150x106/l: results of the Zidon trial (1995) (26)
Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. (2014) (25)
Use of competitive polymerase chain reaction to determine HIV‐1 levels in response to antiviral treatments (1993) (25)
Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections. (1998) (25)
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients (2012) (25)
Consensus symposium on combined antiviral therapy (1996) (25)
Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe. (2009) (25)
Immune response and epitope mapping of a candidate hiv‐1 p17 vaccine hgp30 (1990) (24)
Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. (1996) (23)
Coronavirus Escape from Heptad Repeat 2 (HR2)-Derived Peptide Entry Inhibition as a Result of Mutations in the HR1 Domain of the Spike Fusion Protein (2007) (23)
Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group. (1995) (23)
Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug-resistance: the CATCH study (2003) (23)
Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor (1995) (23)
Baseline CD4+ T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients (2011) (23)
HIV-1 RNA levels in the cerebrospinal fluid may increase owing to damage to the blood-brain barrier. (1997) (22)
HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. (1999) (22)
How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts’ Opinion and Its Influence on the Projected Public Health Impact (2016) (22)
Prevalence of transmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH-Study (2003) (22)
H 1 N 1 2009 Pandemic Influenza Virus : Resistance of the I 223 R Neuraminidase Mutant Explained by Kinetic and Structural Analysis (2012) (22)
Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study (2015) (21)
The potential for multidrug-resistant influenza (2011) (21)
Securing sustainable funding for viral hepatitis elimination plans (2019) (21)
Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. (2006) (21)
The xenotropic murine leukemia virus-related retrovirus debate continues at first international workshop (2010) (21)
Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. (2001) (21)
Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity (2012) (20)
Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients. (1998) (20)
Clinical experience with non-nucleoside reverse transcriptase inhibitors. (1997) (20)
Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir (2020) (20)
Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity (2014) (20)
Persistent human immunodeficiency virus type 1 antigenemia in children correlates with disease progression. (1988) (20)
Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients. (2002) (19)
Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058 (2019) (19)
Virological failure and drug resistance during first line anti‐retroviral treatment in Indonesia (2013) (18)
Efficacy of the Latest Generation of Antibody Assays for (Early) Detection of HIV 1 and HIV 2 Infection (1989) (18)
Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS) (2019) (18)
Zika Virus: Where Is the Treatment? (2016) (18)
Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase (2008) (17)
Antibody response to a synthetic peptide covering a LAV-1/HTLV-IIIB neutralization epitope and disease progression. (1989) (17)
Ongoing HIV Replication in Cerebrospinal Fluid under Successful Monotherapy (2013) (16)
HIV protease resistance and viral fitness (2007) (16)
Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients (2017) (16)
Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels. (2001) (16)
Antibody response to human immunodeficiency virus type 1 protease according to risk group and disease stage (1989) (16)
Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study. (2016) (15)
Mutation V111I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K65R and Q151M Viruses (2014) (15)
Efficient inhibition of both syncytium‐inducing and non‐syncytium‐inducing wild‐type HIV‐1 by lamivudine in vivo (1998) (15)
State of the Art in HIV Drug Resistance: Science and Technology Knowledge Gap. (2018) (15)
HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries. (2010) (15)
Development of C-TILDA: a modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1. (2019) (14)
Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe. (2015) (14)
Effect of Weekly Adefovir (PMEA) Infusions on HIV-1 Virus Load: Results of a Phase I/II Study (1998) (14)
Viral Shedding and Susceptibility to Oseltamivir in Hospitalized Immunocompromised Patients with Influenza in the Influenza Resistance Information Study (IRIS) (2015) (14)
Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs (2020) (14)
Summary of the III International Consensus Symposium on Combined Antiviral Therapy. (1998) (13)
A novel genetic pathway involving L76V and M46I leading to lopinavir/r resistance (2007) (13)
Strengthening the diagnostic capacity to detect Bio Safety Level 3 organisms in unusual respiratory viral outbreaks. (2009) (13)
Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts (2019) (13)
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores (2007) (13)
Epidemiological impact and cost‐effectiveness of providing long‐acting pre‐exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study (2019) (13)
Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand (2018) (12)
Novel mechanisms of HIV protease inhibitor resistance (2008) (12)
Insertions in the beta3-beta4 loop of reverse transcriptase of human immunodeficiency virus type 1 and their mechanism of action, influence on drug susceptibility and viral replication capacity. (2007) (12)
Antigenicity of linear B-cell epitopes in the C1, V1, and V3 region of HIV-1 gp 120. (1989) (12)
Practical guidelines in antiviral therapy (2002) (12)
Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency (2019) (12)
Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon &agr;-2a: progressive decrease in hepatitis B surface antigen in responders (2012) (12)
ViroLab: A collaborative decision support system in viral disease treatment (2008) (12)
Transmission of HIV and AIDS by plasmapheresis for Guillain-Barré Syndrome (1988) (12)
Hepatitis C virus and human immunodeficiency virus coinfection: where do we stand? (2005) (11)
Transmission of drug-resistance in Europe is characterized by single mutations and revertants (2006) (11)
Management of drug interactions with direct‐acting antivirals in Dutch HIV/hepatitis C virus‐coinfected patients: adequate but not perfect (2018) (11)
Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model (2014) (10)
Insights on transmission of HIV from phylogenetic analysis to locally optimize HIV prevention strategies (2017) (10)
Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study Group. (1996) (10)
Treatment of hepatitis C monoinfection in adults--Dutch national guidelines. (2013) (10)
Therapy Failure Resulting from Superinfection by a Drug-Resistant HIV Variant (2012) (10)
A Polymorphism at Position 400 in the Connection Subdomain of HIV-1 Reverse Transcriptase Affects Sensitivity to NNRTIs and RNaseH Activity (2013) (10)
Broad Advances in Understanding HIV Resistance to Antiretrovirals: Report on the XVII International HIV Drug Resistance Workshop (2008) (10)
Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance (2017) (10)
8 EARLY PREDICTION OF SUSTAINED RESPONSE TO PEGINTERFERON ALFA-2A IN HBEAG-NEGATIVE PATIENTS: THE ROLE OF ON-TREATMENT HBSAG AND HBV DNA LEVELS (2010) (9)
Implications of HIV Drug Resistance on First- and Second-Line Therapies in Resource-Limited Settings: Report from a Workshop Organized by the Collaborative HIV and Anti-HIV Drug Resistance Network (2013) (9)
Clinical Implications of Resistance to Antiretrovirals: New Resistance Technologies and Interpretations (2008) (9)
Novel metric for evaluating pre-exposure prophylaxis programme effectiveness in real-world settings. (2020) (9)
Selective transmission of drug resistance mutations (2005) (9)
The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count) (2003) (9)
Case report: Oseltamivir‐induced resistant pandemic influenza A (H1N1) Virus infection in a patient with AIDS and Pneumocystis jirovecii pneumonia (2013) (9)
The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C (2018) (8)
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial. (1999) (8)
Estimates of HIV transmitted drug resistance can be inflated due to natural sequence polymorphisms. (2011) (8)
HOMOLOGOUS RECOMBINATION FOR RAPID PHENOTYPING OF HIV (1997) (8)
Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey (2019) (8)
Evolution of a novel 5-amino-acid insertion in the β3-β4 loop of HIV-1 reverse transcriptase (2007) (7)
Hepatitis B virus prevalence, risk factors and genotype distribution in HIV infected patients from West Java, Indonesia. (2014) (7)
Initial appearance of the 184 I 1 e variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase (1997) (7)
Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group. (1995) (7)
Multi-Science Decision Support for HIV Drug Resistance Treatment (2008) (7)
Antigenic variation of the dominant gp41 epitope in Africa. (1993) (7)
Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine. (1997) (7)
Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance. (2015) (7)
Early recovery of CD 4 + T lymphocytes in children on highly active antiretroviral therapy (1998) (7)
[Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells]. (2004) (7)
Treatment of Immunocompromised, Critically Ill Patients with Influenza A H1N1 Infection with a Combination of Oseltamivir, Amantadine, and Zanamivir (2015) (6)
Transmission of NS5A-Inhibitor Resistance-Associated Substitutions Among Men Who Have Sex With Men Recently Infected with Hepatitis C Virus Genotype 1a (2020) (6)
VIROLAB - A virtual Laboratory for Decision Support in Viral Diseases Treatment (2005) (6)
Differences in the frequency of minor substitutions between HIV-1 subtypes and their potential impact on the genetic barrier for resistance to protease inhibitors (2005) (6)
Changes in HIV Gag and protease cannot explain persistent viraemia in the majority of patients failing first-line lopinavir/ritonavir therapy (2007) (6)
Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA (2020) (6)
HIV drug resistance tests are here to stay. (1999) (6)
A Real World Resistance Profile of Virologic Failures Collected from an International Collaboration (SHARED) (2018) (6)
HIV and Hepatitis Virus Resistance to Antivirals: Review of Data from the Xix International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies (2011) (5)
Summary of the II international consensus symposium on combined antiviral therapy and implications for future therapies (1997) (5)
Significant Impact of Coronavirus Disease 2019 (COVID-19) on Human Immunodeficiency Virus (HIV) Care in Hospitals Affecting the First Pillar of the HIV Care Continuum (2022) (5)
Two highly antigenic sites in the human immunodeficiency virus type 1 reverse transcriptase (1993) (5)
Influenza A(H1N1) Oseltamivir Resistant Viruses in the Netherlands During the Winter 2007/2008 (2011) (5)
No predictive value of GC phenotypes for HIV infection and progression to AIDS (1988) (5)
Low cost HIV-1 quantitative RT-PCR assay in resource-limited settings: improvement and implementation. (2012) (5)
A systematic approach that identifies 11 new mutations as indicators of transmission of resistance (2003) (4)
A grid-based problem-solving environment for biomedicine (2003) (4)
State of the antiretroviral therapy in human immunodeficiency virus drug resistance (2018) (4)
Mutation V 111 I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K 65 R and Q 151 M Viruses (2019) (4)
Targeted HCV core antigen monitoring among HIV-positive men who have sex with men is cost-saving (2019) (3)
Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals (1996) (3)
[Post-exposure prophylaxis following exposure to HIV: adaptation to the situation may be indicated]. (2005) (3)
Significant impact of COVID-19 on HIV care in hospitals affecting the first pillar of the HIV care continuum (2021) (3)
Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase. (2007) (3)
Progress in Basic and Clinical Research on HIV Resistance: Report on the XVIII International HIV Drug Resistance Workshop (2009) (3)
Unite forces to validate biomarkers in the quest for lasting HIV remission. (2016) (3)
Second European Round Table on the Future Management of HIV (2015) (3)
Stochastic Modeling of Temporal Variability of HIV-1 Population (2003) (3)
Serum reactivity to HIV-1 accessory gene products distinguishes East African from West African HIV strains as infecting agent. (1989) (3)
Resistance to protease inhibitors (2006) (3)
State of the Art in HIV Drug Resistance: Surveillance and Regional Gaps. (2018) (3)
Tree models for the evolution of drug resistance (2003) (3)
Key Reports from the XV International HIV Drug Resistance Workshop 2006 (2007) (3)
Ending the epidemic: Critical role of primary HIV infection. (2017) (2)
The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures (2021) (2)
Test and treat for prevention of new HIV infections (2010) (2)
[HIV should become a notifiable disease]. (2007) (2)
Monitoring transmission of drug resistant HIV to develop a strategy to control spread of resistance: the SPREAD network (2004) (2)
Ending AIDS as a Public Health Threat by 2030: Scientific Developments from the 2016 Interest Conference in Yaoundé, Cameroon (2017) (2)
[AIDS; new developments. II. Treatment of HIV infection]. (1997) (2)
750 A COMPARISON OF TWO ASSAYS FOR QUANTIFICATION OF HEPATITIS B SURFACE ANTIGEN IN SERUM OF PATIENTS WITH CHRONIC HEPATITIS B (2011) (2)
Viral resistance: a major challenge in managing HIV disease. (1995) (2)
Corrigendum to “Strengthening the diagnostic capacity to detect Bio Safety Level 3 organisms in unusual respiratory viral outbreaks” [J. Clin. Virol. 45 (2009) 185–190] (2010) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
HIV resistance assay results and their effect on therapeutic decisions. (2001) (2)
Classes of Antiviral Drugs (2002) (1)
Determination of the optimal cut-offs for predicting the phenotype of nine different HIV drug-resistance algorithms (2002) (1)
The calculated genetic barrier for drug resistance mutations in six different non-B subtypes and two CRFs in a large European dataset is largely similar to subtype B (2004) (1)
[Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine]. (2013) (1)
Virolab: A Distributed Decision Support System for Viral Disease Treatment (2008) (1)
Emergence of oseltamivir resistant influenza A (H1N1) viruses in the Netherlands during the winter 2007/2008. (2008) (1)
In-vitro selection of HIV-1 variants resistant to non-nucleoside reverse transcriptase inhibitors in monocyte-derived macrophages. (1997) (1)
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics (2013) (1)
Fourth International Workshop : abstracts presented at a Workshop held in Sardinia, Italy on July 6-9, 1995 (1995) (1)
Limited cross-border infections in patients newly diagnosed with HIV in Europe (2013) (1)
383 HEPATITIS B AWARENESS AND SCREENING PROGRAMMES FOR CHINESE COMMUNITIES IN THE NETHERLANDS: SUCCESSFUL IDENTIFICATION OF PATIENTS WITH ACTIVE LIVER DISEASE (2011) (1)
Clinical significance of zidovudine-resistant human immunodeficiency viruses. (1992) (1)
Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity (2014) (1)
The Xivth International HIV Drug Resistance Workshop, Quebec City, Canada, June 2005 (2005) (1)
[Fatal pneumonitis due to oseltamivir-resistant new influenza A(H1N1) in the case of an intensive care patient]. (2010) (1)
Author response: Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma (2021) (1)
[Combating the new influenza A (H1N1) virus. I. Overview of the relevant virological aspects]. (2009) (1)
How testing for HIV resistance influences therapeutic decision making. Analysis of a sample of 600 clinicians. (2001) (1)
Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model (2014) (1)
[Vertical HIV-I-transmission. I. Risk and prevention in pregnancy]. (1998) (1)
HIV Variation: Consequences for antiviral therapy and disease progression (1995) (1)
Drug susceptibility patterns in 2000 patients de novo infected with drug resistant virus: implications for first-line antiretroviral therapy and PEP (2003) (0)
[Increased serum level of naive CD8+-T-cells during intensive antiretroviral therapy]. (1998) (0)
Aciclovir for dual infection with HIV and HSV. (2012) (0)
CHAPTER 62 – Surveillance of Antiretroviral Drug Resistance in Resource-poor Settings (2008) (0)
THU-169-Genotype 4 RAS patterns in a European hepatitis C cohort (2019) (0)
Correlation between estimated fitness under protease and reverse transcriptase inhibitor selective pressure and viral load or CD4 count in recently diagnosed treatment-naïve patients (2008) (0)
Frequency of primary reistance in subtype B is significantly lower in Europe compared to the US; analysis of 1400 patients from 16 countries: the CATCH-Study (2003) (0)
Chapter 32 Molecular Mechanisms of Resistance to Nucleoside Reverse Transcriptase Inhibitors (0)
Immune-Escape Mutations and Stop-Codons in HBsAg Circulates in a Relevant Proportion of Patients with Chronic HBV Infection Exposed to Anti-HBV Drugs in Europe: Implications for HBV Transmission in the Setting of Vaccination and Disease Progression (2016) (0)
Aids; a retrovirus infection in humans (1998) (0)
[Dendritic cells as carriers of human immunodeficiency virus (HIV)]. (2000) (0)
articleIdentifying potential survival strategies of HIV-1 through virus-host protein interaction networks (2010) (0)
Molecular Mechanisms of Resistance to Nucleoside Reverse Transcriptase Inhibitors (2009) (0)
UvA-DARE ( Digital Academic Repository ) A Grid-Based Hiv Expert System (2005) (0)
A Grid-based HIVExpert System (2005) (0)
Initial appearance of the 184I1e variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase (1997) (0)
State of the antiretroviral therapy in human immunodeficiency virus drug resistance: Surveillance and regional gaps (2018) (0)
Announcements and Call for Abstracts (2009) (0)
NACCAP ART-A - Programme for developing an Affordable HIV drug Resistance Test for Africa. (2007) (0)
As a stone thrown in a still pond : predicting human influenza epidemiological dynamics after 2009 A/pH1N1 pandemic explosion (2016) (0)
Quality of Life Among People Living With HIV in England and the Netherlands Comparable to the General Population (2021) (0)
Significant Impact of COVID-19 on the First Pillars of the HIV Care Continuum (2021) (0)
Dynamics on and of biological networks : Case studies on the machinery of life (0)
A GRID-BASED HIV EXPERT SYSTEM 1 (2005) (0)
Title Extracting causal relations on HIV drug resistance fromliterature (2018) (0)
Edinburgh Research Explorer Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals (2018) (0)
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients (2012) (0)
Regional Customization of EGEE Infrastructure in Central Europe (0)
UvA-DARE ( Digital Academic Repository ) Identifying potential survival strategies of HIV-1 through virus-host protein interaction networks (2010) (0)
A19 The origin of acute HCV in HIV-infected men who have sex with men in the Netherlands (2019) (0)
High-Dos eNevirapin ei nPreviousl yUntreate dHuma nImmunodeficienc yVirus Typ e1-Infecte dPerson sDoe sNo tResul ti nSustaine dSuppressio no fViral Replication (1997) (0)
Fatal pneumonitis due to oseltamivir-resistant new influenza A(H1N1) in an intensive care patient (2010) (0)
No HIV infections despite high numbers of hepatitis B and C virus infections in Dutch prisoners (2011) (0)
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance (2015) (0)
Chapter 163 – Retroviruses and retroviral infections (2010) (0)
Transmission of Resistant Viruses (2000) (0)
Chapter 3 HIV-1 resistance dynamics in patients with virological failure to dolutegravir maintenance monotherapy . (2018) (0)
Validation of molecular indicators of resistance transmission (MIRTs) for epidemiological studies of drug resistance transmission in HIV (2004) (0)
Reply to Darcis and Berkhout. (2018) (0)
Genetic diversity of HIV-1 in Europe and its demographic determinants (2002-2005) (2011) (0)
Tolerability and activity of a new recombinant interferon-alpha B/D hybrid in patients with HIV-1 infection. (1996) (0)
An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini. (1995) (0)
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) (2021) (0)
Reverse transcription fitness assay by quantitative determination of intermediate HIV-1 reverse transcription cDNA products in PBMCs (2003) (0)
Individualisation of HIV therapy based on HIV RNA load: the virologist's perspective. (1996) (0)
Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases. (1996) (0)
Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients (2017) (0)
Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity (2012) (0)
TREATMENT-ASSOCIATED POLYMORPHISMS IN PROTEASE BUT NOT IN REVERSE TRANSCRIPTASE ARE SIGNIFICANTLY ASSOCIATED WITH HIGHER VIREMIA AND LOWER CD4 CELL COUNT IN RECENTLY DIAGNOSED TREATMENT-NAIVE PATIENTS (2010) (0)
File Id 205572 Filename Chapter 2: Hiv Decision Support: from Molecule to Man Source (or Part of the following Source): Type Dissertation Title a Multi-scale Approach for Deciphering Hiv Infection Hiv Decision Support: from Molecule to Man Background (2011) (0)
Persistent Transmission of HCV among Men Who Have Sex with Men despite Widespread Screening and Treatment with Direct-Acting Antivirals (2022) (0)
S133 Resistance to anti-retroviral drugs (1997) (0)
Chapter 2 Dolutegravir as maintenance monotherapy for HIV ( DOMONO ) : a phase 2 , randomised non-inferiority trial (2018) (0)
Susceptibility of influenza B viruses to neuraminidase inhibitors: findings from the first 4 years (2008–2012) of the global Influenza Resistance Information Study (IRIS) (2013) (0)
[Vertical HIV-I-transmission. II. HIV-diagnosis in a child]. (1998) (0)
Potential impact of differences in frequency of minor substitutions between HIV-1 subtypes on the genetic barrier for resistance to protease inhibitors (2005) (0)
Anti-CD3 induced HIV replication in vivo (1998) (0)
1021 HBSAG LEVELS DURING ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS B: PEGINTERFERON VERSUS ENTECAVIR (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Charles A. B. Boucher?

Charles A. B. Boucher is affiliated with the following schools:

Charles A. B. Boucher's Academic­Influence.com Rankings

Why Is Charles A. B. Boucher Influential?

Charles A. B. Boucher's Published Works

Published Works

What Schools Are Affiliated With Charles A. B. Boucher?

Charles A. B. Boucher's AcademicInfluence.com Rankings